Scout | Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

This opportunity is no longer accepting applications.

grant

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

The National Cancer Institute is inviting applications for a grant aimed at validating biomarkers and assays used in cancer detection, diagnosis, prognosis, and treatment. This opportunity focuses on both analytical and clinical validation of these assays, which must work on human samples. The UH2 phase involves analytical validation over 2 years, while the UH3 phase covers clinical validation…

Source

Agency: National Institutes of Health

Program: SBIR

Award

Award Ceiling: $275,000

Funding Amount: $275,000

Dates

Opportunity Released: November 1, 2023

Open for Submission: November 1, 2023

Submission Deadline: October 14, 2026

Application Window Closes: October 14, 2026

Keywords

Cancer

Biomarkers

Assay Validation

Clinical Studies

Molecular Markers

Imaging Markers

Cancer Detection

Cancer Prognosis

Pharmacodynamic Markers

Immunotherapy

Supporting Links

Documents

Similar Opportunities

Unlock similar opportunities

Get the full picture on this opportunity

Create a free Scout account to unlock everything you need to decide fast and win the grant.

Instant Fit Analysis

Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
Deep agency & funder detail

Program context, sub-agency structure, and a full eligibility breakdown.
Source links & full documents

Jump straight to the solicitation and download every attachment.
Similar opportunities

Discover related funding matched to your work.

Get a Demo Sign Up

Already have an account? Sign In

Trusted by 500+ Happy Customers